<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629455</url>
  </required_header>
  <id_info>
    <org_study_id>AB-1001</org_study_id>
    <nct_id>NCT05629455</nct_id>
  </id_info>
  <brief_title>CareSuperb COVID-19 Antigen Test Usability</brief_title>
  <official_title>CareSuperb COVID-19 Antigen Home Test Usability Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AccessBio, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AccessBio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the usability of the CareSuperb COVID-19 Antigen&#xD;
      Home Test in Home Use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19 is a contagious respiratory illness, caused by infection with the novel coronavirus&#xD;
      Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This communicable disease is&#xD;
      easily transmitted through aerosolized droplets containing the infectious virus. Infections&#xD;
      with SARS-CoV-2 can have varying degrees of signs and symptoms, ranging from asymptomatic to&#xD;
      severe. Individuals infected with SARS-CoV-2 are believed to be contagious from as early as&#xD;
      two days prior to symptom onset to at least ten days after the onset of symptoms. The rapid&#xD;
      detection of infections and contacts and the implementation of infection control measures are&#xD;
      critical for mitigation of this virus.&#xD;
&#xD;
      The CareSuperb COVID-19 Antigen Home Test is a lateral flow immunochromatographic assay&#xD;
      intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2&#xD;
      from individuals with or without symptoms or other epidemiological reasons to suspect a&#xD;
      COVID-19 infection. This kit is intended for non-prescription home use with self-collected&#xD;
      direct anterior nares swab samples from individuals ages 14 years and older or adult lay&#xD;
      user-collected anterior nares swab samples from individuals aged 2 to 13 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 17, 2022</start_date>
  <completion_date type="Actual">November 22, 2022</completion_date>
  <primary_completion_date type="Actual">November 22, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open label study to evaluate the usability of the CareSuperb COVID-19 Antigen Home Test using information from the Quick Reference Instructions (QRI).</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Usability of Quick Reference Instruction</measure>
    <time_frame>One month</time_frame>
    <description>Primary Endpoints: 1. Assess the usability of the Quick Reference Instructions (QRI) based upon observer evaluation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Usability of Test Kit</measure>
    <time_frame>One month</time_frame>
    <description>Primary Endpoints: 2. Assess the usability of the kit for home use based upon subject evaluation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>individuals ages 14 years and older</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>individuals aged 2 to 13 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples.&#xD;
If the subject is under the age of 14, an adult lay-user will collect the sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CareSuperb COVID-19 Antigen Home Test Kit</intervention_name>
    <description>At home COVID-19 antigen test kit</description>
    <arm_group_label>individuals aged 2 to 13 years</arm_group_label>
    <arm_group_label>individuals ages 14 years and older</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. An Institutional Review Board (IRB) approved informed consent / assent, if applicable,&#xD;
             is signed and dated prior to any study-related activities.&#xD;
&#xD;
          2. Male and female subjects 2 years of age and older.&#xD;
&#xD;
          3. Subject is willing to provide a self-collected nasal swab sample. (If the subject is&#xD;
             under the age of 14, an adult lay-user will collect the sample.)&#xD;
&#xD;
          4. Subject agrees to complete all aspects of the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subject has a visual impairment that cannot be restored with glasses or contact&#xD;
             lenses.&#xD;
&#xD;
          2. Subject has prior medical or laboratory training.&#xD;
&#xD;
          3. Subject uses home diagnostics, e.g., glucose meters, HIV tests.&#xD;
&#xD;
          4. Subject has prior knowledge of their current COVID-19 infection status.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Villa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>L&amp;A Morales Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>L&amp;A Morales Healthcare Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 18, 2022</study_first_submitted>
  <study_first_submitted_qc>November 18, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>February 2, 2023</last_update_submitted>
  <last_update_submitted_qc>February 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

